29 series
Export
<<< of 2>>>
Accession Title Series type(s) Organism(s) Samples GDS Supplementary Contact Release date
Remove filtersFilter Remove filterExpression profiling by array Remove filterLars Bullinger
GSE62533
Inhibitor of apoptosis proteins as promising therapeutic targets in chronic lymphocytic leukemia
  • Expression profiling by array
12 Profile icon Lars Bullinger Mar 31, 2015
GSE29883
Deregulated apoptosis signaling in core binding factor leukemia differentiates clinically relevant, molecular marker independent subgroups
  • Expression profiling by array
12 Profile icon Lars Bullinger Jun 11, 2011
GSE11572
Klf4
  • Expression profiling by array
12 Lars Bullinger Jul 31, 2012
GSE12278
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
  • Expression profiling by array
6 Lars Bullinger Jul 31, 2008
GSE12400
Analysis of MYC in murine lymphoma cell lines
60 Lars Bullinger Aug 12, 2008
GSE15151
Synthetic Lethal Interaction Between Oncogenic KRAS Dependency and Suppression of STK33 in Human Cancer Cells
  • Expression profiling by array
8 Lars Bullinger Jun 24, 2009
GSE15913
Thalidomide Exerts Distinct Molecular Antileukemic Effects
  • Expression profiling by array
40 Lars Bullinger Aug 21, 2009
GSE16432
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
  • Expression profiling by array
436 Lars Bullinger Jul 11, 2010
GSE23143
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.
  • Expression profiling by array
253 Lars Bullinger Jun 27, 2011
GSE23312
RUNX1 mutated cases in acute myeloid leukemia share a distinct biological subgroup and are associated with inferior outcome. Results of the AML Study Group (AMLSG).
  • Expression profiling by array
269 Lars Bullinger Dec 31, 2010
GSE24384
Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML
  • Expression profiling by array
2 Lars Bullinger Oct 26, 2010
GSE31644
Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia
  • Expression profiling by array
43 Lars Bullinger Sep 12, 2011
GSE32246
TET2 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis of the AML Study Group (AMLSG)
  • Expression profiling by array
333 Lars Bullinger Dec 31, 2011
GSE35219
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
13 Lars Bullinger Aug 14, 2012
GSE39363
A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy
  • Expression profiling by array
13 Lars Bullinger Dec 31, 2014
GSE39730
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance
  • Expression profiling by array
12 Lars Bullinger Aug 03, 2012
GSE40939
Leukemogenesis by CDX2 involves KLF4 repression and deregulated PPARgamma signaling.
  • Expression profiling by array
10 Lars Bullinger Dec 21, 2012
GSE43258
PRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17)
  • Expression profiling by array
6 Lars Bullinger Mar 10, 2013
GSE46819
Inhibitor of apoptosis protein antagonist BV6 – potential for new combinatorial treatment strategies in acute myeloid leukemia
  • Expression profiling by array
24 Lars Bullinger Dec 31, 2014
GSE54223
Phospholipase Cγ1 is crucially required for EpoR/JAK2 controlled erythropoietic differentiation.
  • Expression profiling by array
12 Lars Bullinger Dec 31, 2014